UNSPSC 51282921: Gatifloxacin

This classification denotes a quinolone antibiotic with the molecular formula 2C19H22FN3O4.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, L4618BD7KJ chemically known as (+/-)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid, sesquihydrate but generally known as gatifloxacin, which bears US NIH Compound Identifier 5379. European Medicines Agency schedules Gatifloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13952MIG.

UNSPSC 51282921 Gatifloxacin, a Commodity code, nominally covers a single fluoroquinolone antibiotic; however, recent state and local opportunities tagged under this code show little direct procurement of gatifloxacin itself and instead reflect broader pharmaceutical, medical supply, and pharmacy benefit program sourcing. The issuing bodies across recent opportunities span state health and human services agencies, county public health departments, and municipal fire and rescue divisions — reflecting the wide range of entities acquiring pharmaceuticals and medical supplies through bulk procurement and cooperative purchasing agreements. Work being solicited includes emergency medical and first aid supplies (bandaging, airway devices, cardiac monitoring equipment, respiratory protection), naloxone and drug deactivation systems for community health initiatives, generic multi-source pharmaceuticals and over-the-counter products through state cooperative purchasing vehicles, and pharmacy benefit program strategy consultation regarding direct-to-manufacturer prescription sourcing.

Geographic activity centers on Florida (Seminole County IFB for naloxone and drug deactivation systems, posted June 30, 2026, response due July 26, 2023), Texas (Texas Health and Human Services Commission RFI for direct-to-manufacturer prescription programs, posted April 3, 2026), and Minnesota (Minnesota Multistate Cooperative Purchasing Alliance RFP for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026, response due March 26, 2026, serving Minnesota and Oregon). The City of Tampa's March 2026 IFB for medical and first aid supplies to the Fire Department Rescue Division — estimated at $700,000, with sealed-bid response due March 13, 2026, and designated as a sheltered-market procurement for certified Small Local Business Enterprises — represents representative municipal demand for emergency medical consumables. The Minnesota cooperative purchasing RFP demonstrates state and local reliance on multi-vendor, multi-state wholesaler models for pharmaceutical distribution, with incumbent and new responder participation through June 2028 and optional extensions. The code's recent record shows minimal activity directly aligned with gatifloxacin procurement; opportunities tagged to this code predominantly address broader medical supply and pharmacy program sourcing rather than fluoroquinolone-specific pharmaceutical contracting.